TY - JOUR
T1 - Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue
T2 - a study protocol for a randomized controlled trial
AU - Mikkelsen, Rasmus Kramer
AU - Blønd, Lars
AU - Hölmich, Lisbeth Rosenkrantz
AU - Mølgaard, Cecilie
AU - Troelsen, Anders
AU - Hölmich, Per
AU - Barfod, Kristoffer Weisskirchner
N1 - © 2021. The Author(s).
PY - 2021/10/27
Y1 - 2021/10/27
N2 - BACKGROUND: Osteoarthritis is a destructive joint disease that leads to degeneration of cartilage and other morphological changes in the joint. No medical treatment currently exists that can reverse these morphological changes. Intra-articular injection with autologous, micro-fragmented adipose tissue has been suggested to relieve symptoms.METHODS/DESIGN: The study is a blinded randomized controlled trial with patients allocated in a 1:1 ratio to 2 parallel groups. Patients suffering from pain and functional impairment due to osteoarthritis Kellgren-Lawrence grades 2-3 in the tibiofemoral joint are eligible for inclusion. The intervention group is treated with an intra-articular injection with autologous, micro-fragmented adipose tissue prepared using the Lipogems® system. The control group receives an intra-articular injection with isotonic saline. In total, 120 patients are to be included. The primary outcome is The Knee injury and Osteoarthritis Outcome Score (KOOS4) evaluated at 6 months. Secondary outcomes are KOOS at 3, 12 and 24 months; the Tegner activity score; treatment failure; and work status of the patient. The analysis will be conducted both as intention-to-treat and per-protocol analysis.DISCUSSION: This trial is the first to investigate the efficacy of autologous, micro-fragmented adipose tissue in a randomized controlled trial. The study uses the patient-reported outcome measure Knee Injury and Osteoarthritis Outcome Score (KOOS4) after 6 months as the primary outcome, as it is believed to be a valid measure to assess the patient's opinion about their knee and associated problems when suffering from osteoarthritis.
AB - BACKGROUND: Osteoarthritis is a destructive joint disease that leads to degeneration of cartilage and other morphological changes in the joint. No medical treatment currently exists that can reverse these morphological changes. Intra-articular injection with autologous, micro-fragmented adipose tissue has been suggested to relieve symptoms.METHODS/DESIGN: The study is a blinded randomized controlled trial with patients allocated in a 1:1 ratio to 2 parallel groups. Patients suffering from pain and functional impairment due to osteoarthritis Kellgren-Lawrence grades 2-3 in the tibiofemoral joint are eligible for inclusion. The intervention group is treated with an intra-articular injection with autologous, micro-fragmented adipose tissue prepared using the Lipogems® system. The control group receives an intra-articular injection with isotonic saline. In total, 120 patients are to be included. The primary outcome is The Knee injury and Osteoarthritis Outcome Score (KOOS4) evaluated at 6 months. Secondary outcomes are KOOS at 3, 12 and 24 months; the Tegner activity score; treatment failure; and work status of the patient. The analysis will be conducted both as intention-to-treat and per-protocol analysis.DISCUSSION: This trial is the first to investigate the efficacy of autologous, micro-fragmented adipose tissue in a randomized controlled trial. The study uses the patient-reported outcome measure Knee Injury and Osteoarthritis Outcome Score (KOOS4) after 6 months as the primary outcome, as it is believed to be a valid measure to assess the patient's opinion about their knee and associated problems when suffering from osteoarthritis.
KW - Adipose Tissue
KW - Humans
KW - Injections, Intra-Articular
KW - Knee Joint/diagnostic imaging
KW - Osteoarthritis, Knee/diagnostic imaging
KW - Randomized Controlled Trials as Topic
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85117899540&partnerID=8YFLogxK
U2 - 10.1186/s13063-021-05628-4
DO - 10.1186/s13063-021-05628-4
M3 - Journal article
C2 - 34706757
VL - 22
SP - 1
EP - 11
JO - Trials
JF - Trials
SN - 1745-6215
IS - 1
M1 - 748
ER -